MOESM1 of Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Additional file 1: Figure S1. Schematic of the cohort-based Markov simulation model

Additional file 1: of Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)

Codes used to identify patients, exposure and outcomes. (DOCX 122 kb

Estimated per patient costs (£000s) related specifically to HCV related complications (excluding any HCV therapy costs) stratified by age, discounting, fibrosis stage and SVR.

<p>Estimated per patient costs (£000s) related specifically to HCV related complications (excluding any HCV therapy costs) stratified by age, discounting, fibrosis stage and SVR.</p

Estimated per-patient life expectancy stratified by age, discounting, current fibrosis stage and SVR.

<p>Estimated per-patient life expectancy stratified by age, discounting, current fibrosis stage and SVR.</p

Modelling assumptions utilised when populating the MONARCH model with study-specific input data.

<p>Modelling assumptions utilised when populating the MONARCH model with study-specific input data.</p

Default disease state transition rates applied in the model.

<p>*Transition rates are influenced by the coefficients presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0117334#pone.0117334.t002" target="_blank">Table 2</a>; rates presented here are the mean values as reported in the original study.</p><p>Default disease state transition rates applied in the model.</p

Flow diagram of the MONARCH model.

<p>Flow diagram of the MONARCH model.</p

Log-linear regression equation coefficients used to derive age dependent fibrosis stage specific transition probabilities.

<p>Source: All risk factors are described as in the source publication, Thein <i>et al</i>. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0117334#pone.0117334.ref016" target="_blank">16</a>].</p><p>Log-linear regression equation coefficients used to derive age dependent fibrosis stage specific transition probabilities.</p

Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.

<p>Estimated per-patient QALYs stratified by age, discounting, current fibrosis stage and SVR.</p

Predicted rates of liver-related mortality (validation to [26, 27]) (left) and all-cause mortality (UK life tables) (right) as estimated by the MONARCH model.

<p>Predicted rates of liver-related mortality (validation to [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0117334#pone.0117334.ref026" target="_blank">26</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0117334#pone.0117334.ref027" target="_blank">27</a>]) (left) and all-cause mortality (UK life tables) (right) as estimated by the MONARCH model.</p